How to reach and maintain the K/DOQITM recommendations for bone and mineral metabolism in patients undergoing haemodialysis: an efficient strategy;Comment atteindre et maintenir les recommandations K/DOQITM sur le métabolisme phosphocalcique chez les patients dialysés : une stratégie efficace

Nephrologie et Therapeutique

Volumn 3, Issue 1, 2007, Pages 33-42

  Rottembourg, Jacques ^a   Diab, Raji ^a   Boulechfar, Hacène ^a  

^a Centre Suzanne Levy   (France)

Author keywords

Chronic kidney disease; Hyperphosphatemia; K DOQI guidelines; Metabolic bone disease; Secondary hyperparathyroidism

Indexed keywords

ALFACALCIDOL; BICARBONATE; CALCIUM; CALCIUM CARBONATE; CHOLESTEROL; CINACALCET; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PHOSPHATE BINDING AGENT; RECOMBINANT ERYTHROPOIETIN; SEVELAMER; VITAMIN D DERIVATIVE; CHELATING AGENT; MINERAL; POLYAMINE;

ARTICLE; BONE METABOLISM; CALCIUM INTAKE; CHOLESTEROL BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; MINERAL METABOLISM; PARAMETER; PRACTICE GUIDELINE; PRESCRIPTION; AGED; BONE; BONE DISEASE; CLASSIFICATION; KIDNEY DISEASE; METABOLISM; MIDDLE AGED; RENAL REPLACEMENT THERAPY; TREATMENT OUTCOME;

AGED; BONE AND BONES; BONE DISEASES; CHELATING AGENTS; HUMANS; KIDNEY DISEASES; MIDDLE AGED; MINERALS; POLYAMINES; RENAL DIALYSIS; TREATMENT OUTCOME;

EID: 33947325801     PISSN: 17697255     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nephro.2006.11.003     Document Type: Article

References (73)

1. Lowrie E.G., and Lew N.L. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am. J. Kidney Dis. 15 (1990) 458-482
2. Block G.A., Hulbert-Shearon T.E., Levin N.W., and Port F.K. Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients. A national study. Am. J. Kidney Dis. 31 (1998) 607-617
3. Block G.A. Prevalence and clinical consequences of elevated Ca × P product in hemodialysis patients. Clin. Nephrol. 54 (2000) 318-324
4. Block G.A., and Port F.K. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am. J. Kidney Dis. 35 (2000) 1226-1237
5. (4) product and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J. Am. Soc. Nephrol. 12 (2001) 2131-2138
6. Kuzela D.C., Huffer W.E., Conger J.D., et al. Soft tissue calcifications in chronic dialysis patients. Am. J. Pathol. 86 (1977) 403-424
7. Goodman W.G., Goldin J., Kuizon B.D., Yoon C., Gales B., Sider D., et al. Coronary-artery calcification in young adults with end stage renal diseases who are undergoing dialysis. N. Engl. J. Med. 342 (2000) 1478-1483
8. Guerin A.P., London G.M., Marchais S.J., and Metivier F. Arterial stiffening and vascular calcifications in end stage renal disease. Nephrol. Dial. Transplant. 15 (2000) 1014-1021
9. Salusky I.B., and Goodman W.G. Cardiovascular calcifications in end stage renal disease. Nephrol. Dial. Transplant. 17 (2002) 336-339
10. Qunibi W.Y., Nolan C.R., and Ayus J.C. Cardiovascular calcifications in patients with end stage renal disease: a century old phenomena. Kidney Int. Suppl. 82 (2002) 73-80
11. Chertow G.M., Raggi P., Chasan-Taber S., et al. Determinants of progressive vascular calcification in hemodialysis patients. Nephrol. Dial. Transplant. 19 (2004) 1489-1496
12. Burke S.K. Arterial calcification in chronic kidney disease. Sem. Nephrol. 24 (2004) 403-407
13. National Kidney Foundation. K/DOQITM. Clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am. J. Kidney Dis. 42 Suppl. 3 (2003) S1-S202
14. US Renal Data System. USRDS 2004 annual data report: Atlas of End stage renal disease in the United States (2004), National Institute of health, National Institute of diabetes, digestive, and kidney diseases, Bethesda, MD
15. Young E.W., Akiba T., Albert J.M., et al. Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Am. J. Kidney Dis. 44 Suppl. 2 (2004) S34-S38
16. Young E.W., Albert J.M., Sataya-Thum S., Goodkin D.A., Pisoni R.L., Akiba T., et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practices Patterns Study. Kidney Int. 67 (2005) 1179-1187
17. Slatopolsky E.A., and Bricker N.S. The role of phosphorus restriction in the prevention of secondary hyperparathyroidism in chronic renal disease. Kidney Int. 4 (1973) 141-145
18. Slatopolsky E.A., Weer T.S.C., Lopez-Hilker S., et al. Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. N. Engl. J. Med. 315 (1986) 157-161
19. Nolan C.R., and Qunibi W.Y. Calcium salts in the treatment of hyperphosphatemia in hemodialysis patients. Curr. Opin. Nephrol. Hypertens. 12 (2003) 373-379
20. Mai M.L., Emmett M., Sheikh M.S., Santa-Ana C.A., Schiller L., and Fordtran J.S. Calcium-acetate, an effective phosphorus binder in patients with renal failure. Kidney Int. 36 (1989) 690-695
21. Moriniere P., Roussel A., Tahiri Y., De Fremont J.F., Maurel G., Jaudon M.C., et al. Fournier A. Substitution of aluminium hydroxyde by high doses of calcium-carbonate in patients on chronic haemodialysis: disappearance of hyperaluminaemia and equal control of hyperparathyroidism. Proc. Eur. Dial. Transplant Assoc. 19 (1983) 784-787
22. Malluche H.H., and Monier-Faugere M.C. Understanding and managing hyperphosphatemia in patients with chronic renal disease. Clin. Nephrol. 52 (1999) 267-277
23. Hergesell O., and Ritz E. Phosphate binders in uremia: pharmacodynamics, pharmaco economics, pharmaco ethics. Nephrol. Dial. Transplant. 17 (2002) 14-17
24. D'Haese P.C., and De Broe M.E. Aluminum toxicity. In: Daugirdas J.T., and Ing T.S. (Eds). Handbook of dialysis (1994), Little Brown and Company, Boston, New York, Toronto, London 522-545
25. Stedton S.J., Schroeder N.J., and Cunnigham J. Vitamin D analogues: how do they differ and what is their clinical role?. Nephrol. Dial. Transplant. 16 (2001) 1965-1967
26. Malluche H.H., Mawad H., and Koszewski N.J. Update on vitamin D and its newer analogues: actions and rationale for treatment in chronic renal failure. Kidney Int. 62 (2002) 367-374
27. Slatopolsky E.A., Burke S.K., and Dillon M.A. RenaGel, a non-absorbed calcium and aluminium free phosphate binder, lowers serum phosphate and parathyroid hormone. The RenaGel Study Group. Kidney Int. 55 (1999) 299-307
28. Quarles L.D. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism in stage 5 chronic kidney disease. Kidney Int. 68 Suppl. 96 (2005) S21-S28
29. TM bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int. 67 (2005) 760-771
30. Messaï E. Guide des chiffres et formules utilisées en pratique médicale (1995), Ed. Arnette Blackwell, Paris (ISBN / 2-7184-0770-0)
31. Daugirdas J.T., and Greene T. Dialysis dose as a determinant of adequacy. Sem. Nephrol. 25 (2005) 76-80
32. Gonzales E.A., Al-Aly Z., and Martin K.J. Difficulties in achieving the K/DOQI practice guidelines for bone and mineral metabolism. Sem. Dial. 18 (2005) 171-174
33. Al-Aly Z., Gonzales E.A., Martin K.J., and Gellens M.E. Achieving K/DOQI laboratory target values for bone and mineral metabolism: an uphill battle. Am. J. Nephrol. 24 (2004) 422-426
34. Cannata-Andia J., and Diaz-Corte C. Applying the K/DOQI guidelines cut-off levels to the dialysis population. How far are we from the target. J. Am. Soc. Nephrol. 14 (2003) 474A
35. Chertow G.M., Dillon M., Burke S.K., Steg M., Bleyer A.J., Garrett B.N., et al. A randomized trial of sevelamer hydrochloride (Renagel) with and without supplemental calcium. Strategies for the control of hyperphosphatemia and hyperparathyroidism in hemodialysis patients. Clin. Nephrol. 51 (1999) 18-26
36. Chertow G.M., Burke S.K., Dillon M.A., et al. Long term effects of sevelamer hydrochloride on the calcium × phosphate product and lipid profile of haemodialysis patients. Nephrol. Dial. Transplant. 14 (1999) 2907-2914
37. Chertow G.M., Burke S.K., and Raggi P. Treat to Goal Working Group: sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 62 (2002) 242-252
38. Qunibi W.Y., Hootkins R.E., Mc Dowell L.L., Meyer M.S., Simon M., Garza R.O., et al. Treatment of hyperphosphatemia in hemodialysis patients: the Calcium Acetate Renagel Evaluation (CARE Study). Kidney Int. 65 (2004) 1914-1926
39. Sadek T., Mazouz H., Bahloul H., Oprisiu R., El Epser N., El Esper I., et al. Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium versus calcium carbonate in dialysis patients: an open label, randomized study. Nephrol. Dial. Transplant. 18 (2003) 582-588
40. Qunibi W.Y., and Nolan C.R. Treatment of hyperphosphatemia in patients with chronic kidney disease on maintenance hemodialysis: results of the CARE study. Kidney Int. 66 suppl. 90 (2004) S33-S38
41. Bleyer A.J., Burke S.K., Dillon M., Garret B., Kant K.S., Lynch D., et al. A comparison of the calcium free phosphate binder, sevelamer hydrochloride with calcium acetate in the treatment of hyper phosphatemia in hemodialysis patients. Am J Kidney Dis 33 (1999) 694-701
42. Meric F., Yap P., and Bia M.J. Etiology of hypercalcemia in hemodialysis patients on calcium carbonate therapy. Am. J. Kidney Dis. 16 (1990) 459-464
43. Mactier R.A., Van Stone J., Cox A., Van Stone M., and Twardowski Z. Calcium carbonate is an effective phosphate binder when dialysate calcium concentration is adjusted to control hypercalcemia. Clin. Nephrol. 28 (1987) 222-226
44. Pavlovic D., and Brzac H.T. Prevention and treatment of secondary hyperparathyroidism: still a challenge for the nephrologists?. Nephrol. Dial. Transplant. 18 Suppl. 5 (2003) 45-46
45. TM bone metabolism guidelines. Kidney Int. 68 Suppl. 96 (2005) S7-S14
46. Friedman E.A. An introduction to phosphate binders for the treatment of hyperphosphatemia in patients with chronic kidney disease. Kidney Int. 68 Suppl. 96 (2005) S2-S4
47. Friedman E.A. Consequences and management of hyperphosphatemia in patients with renal insufficiency. Kidney Int. 67 Suppl. 95 (2005) S1-S7
48. Alfrey A.C., Le Gendre G.R., and Kaehny W.D. The dialysis encephalopathy syndrome. Possible aluminum intoxication. N. Engl. J. Med. 294 (1976) 184-189
49. Goodman W.G. Recent developments in the management of secondary hyperparathyroidism. Kidney Int. 59 (2001) 1187-1201
50. Coladonato J.A., Szczech L.A., Fridman E.A., and Owen Jr. W.F.W.F. Does calcium kill ESRD patients - the septic's perspective. Nephrol. Dial. Transplant. 17 (2002) 229-232
51. Amin N. The impact of improved phosphorus control: use of sevelamer hydrochloride in patients with chronic renal failure. Nephrol. Dial. Transplant. 17 (2002) 340-345
52. Malluche H.H., and Mawad H. Management of hyperphosphatemia of chronic kidney disease: Lessons from the past and future directions. Nephrol. Dial. Transplant. 17 (2002) 1170-1175
53. Manns B., Stevens L., Miskulin D., Owen Jr. W.F., Winkelmayer W.C., and Tonelli M. A systematic review of sevelamer in ESRD and an analysis of its potential economic impact in Canada and the United States. Kidney Int. 66 (2004) 1239-1247
54. Nolan C.R., and Qunibi W.J. Treatment of hyperphosphatemia in patients with chronic kidney disease on maintenance hemodialysis. Kidney Int. 67 Suppl. 95 (2005) S13-S15
55. Joy M.S., and Finn W.F. LAM-302 Study group. Randomized double blind, placebo, controlled, dose titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate. A new phosphate binder for the treatment of hyperphosphatemia. Am. J. Kidney Dis. 42 (2003) 96-107
56. Behets G.J., Verbeckmoes S.C., Haese P.C., and De Boe M.E. Lanthanum carbonate: a new phosphate binder. Curr. Opin. Nephrol. Hypertens. 13 (2004) 403-409
57. Finn W.F., Joy M.S., Hladik G., and Lanthanum Study Group. Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis. Clin. Nephrol 62 (2004) 193-201
58. Finn W.F., and on the behalf of the SPD 405-307 Lanthanum Study Group. Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients. Clin. Nephrol. 65 (2006) 191-202
59. Indridason O.S., and Quarles L.D. Comparison of treatment for mild secondary hyperparathyroidism in hemodialysis patients. Durham Renal Osteodystrophy Study Group. Kidney Int. 57 (2000) 282-292
60. Brezina B., Qunibi W.Y., and Nolan C.R. Acid loading during treatment with sevelamer hydrochloride: mechanisms and clinical implications. Kidney Int. 66 Suppl. 90 (2004) S39-S45
61. Bailey J.L. Metabolic acidosis: an unrecognized cause of morbidity in the patient with chronic kidney disease. Kidney Int. 68 Suppl. 96 (2005) S15-S23
62. 3 in normal man and patients with renal failure. Ann. Intern. Med. 80 (1974) 161-168
63. Henderson R.G., Russel R.G., Ledingham J.G., Smith R., Oliver D.O., Walton R.J., et al. Effects of 1,25-dihydroxycholcalciferol in calcium absorption, muscle weakness and bone disease in chronic renal failure. Lancet 1 (1974) 379-384
64. Andress D.L., Norris K.C., Coburn J.W., Slatopolsky E.A., and Sherrard D.J. Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N. Engl. J. Med. 321 (1989) 274-279
65. Andress D.L. Vitamin D Treatment in chronic kidney disease. Semin. Dial. 18 (2005) 315-321
66. Levine B.S., and Song M. Pharmacokinetics and efficacy of pulse oral versus intravenous calcitriol in hemodialysis patients. J. Am. Soc. Nephrol. 7 (1996) 488-496
67. 2 (paracalcitriol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J. Am. Soc. Nephrol. 9 (1998) 1427-1432
68. Panda D.K., Miao D., Bolivar I., Li J., Huo R., Hendy G.N., et al. Inactivation of the 25 hydoxyvitamin D 1-alpha-hydroxylase and vitamin D receptor demonstrates independent and interdependent effects of calcium and vitamin D on skeletal and mineral homeostasis. J. Biol. Chem. 279 (2004) 16754-16766
69. Sprague S.M., Llach F., Amdahl M., Taccetta C., and Battle D. Paracalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int. 63 (2003) 1483-1490
70. Block G.A., Martin K.J., de Francisco A.L., et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N. Engl. J. Med. 350 (2004) 1516-1525
71. Achenbach S., Ropers D., Pohle K., et al. Influence of lipid lowering therapy on the progression of coronary artery calcification: a prospective evaluation. Circulation 106 (2002) 1077-1082
72. Wanner C., Krane V., Marz W., Olschewski M., Mann J.F., Ruf G., et al. for the German diabetes and dialysis investigation study. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N. Engl. J. Med. 353 (2005) 224-248
73. Collins A.J., St Peter W.L., Dalleska F.W., et al. Hospitalization risks between Renagel phosphate binder treated and non-Renagel treated patients. Clin. Nephrol. 54 (2000) 334-341